Sanofi Target of Unusually High Options Trading (NYSE:SNY)

Sanofi SA (NYSE:SNY) was the recipient of some unusual options trading on Tuesday. Stock investors purchased 1,391 put options on the stock. This represents an increase of approximately 1,946% compared to the average daily volume of 68 put options.

Institutional investors have recently bought and sold shares of the business. Claybrook Capital LLC purchased a new position in shares of Sanofi during the 4th quarter valued at $31,000. Executive Wealth Management LLC bought a new position in shares of Sanofi during the fourth quarter valued at about $34,000. Nkcfo LLC bought a new position in shares of Sanofi during the first quarter valued at about $35,000. Cullen Frost Bankers Inc. bought a new position in shares of Sanofi during the first quarter valued at about $35,000. Finally, Howe & Rusling Inc. bought a new position in shares of Sanofi during the first quarter valued at about $38,000. 7.04% of the stock is currently owned by hedge funds and other institutional investors.

NYSE SNY traded up $0.38 during trading hours on Thursday, hitting $41.95. The company’s stock had a trading volume of 1,870,500 shares, compared to its average volume of 1,226,320. Sanofi has a 52 week low of $40.19 and a 52 week high of $45.62. The stock has a market capitalization of $104.62 billion, a P/E ratio of 13.40, a PEG ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company’s 50-day moving average price is $42.74.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Friday, April 26th. The company reported $0.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.34 billion. During the same quarter last year, the firm earned $1.28 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 3.1 EPS for the current fiscal year.

Separately, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, June 21st. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and an average price target of $51.00.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: What is a Special Dividend?

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.